Navigation Links
Coherus anuncia início do estudo Fase 3 do CHS-0214 (Biossimilar Investigativo do Etanercept) em psoríase crônica em placas (RaPsOdy)
Date:7/16/2014

/span>, temos o prazer de promover este produto em fase final de desenvolvimento."

"Com dois estudos de fase final agora em andamento em parceria com a Coherus, estamos progredindo com os nossos objetivos coletivos para desenvolver e fornecer alternativas de alta qualidade biológica que atendam às necessidades do paciente", disse Ludwig Hantson, Ph.D., presidente da Baxter BioScience.

Sobre o CHS-0214

O CHS-0214 é uma proposta de biossimilar do etanercept (Enbrel®). Este produto foi avaliado em um estudo cross-over Fase 1 de dose única em voluntários saudáveis. Neste estudo, o CHS-0214 chegou ao endpoint primário da similaridade PK clínica bioequivalência semelhança com o Enbrel®, demonstrando uma média geométrica de 98% entre o CHS-Entre 0214 e o Enbrel®. Nenhuma diferença clinicamente significativa em outros parâmetros de segurança foi observada durante este estudo.

Sobre a Coherus BioSciences, Inc.

A Coherus é uma companhia líder de plataforma de produtos biológicos, concentrada no mercado de biossimilares. Sediada na Área da Baía de San Francisco e fundada por um grupo de pioneiros da biotecnologia, que ajudaram a construir a primeira geração da indústria americana de produtos bioterapêuticos, a Coherus desenvolve um modelo de negócios colaborativo que potencializa um consórcio estratégico de prestadores de serviços especificamente criado para abordar a oportunidade biossimilar para alcançar escala competitiva. As parcerias de comercialização mundial da Coherus incluem companhias biofarmacêuticas globais na Europa, Ásia e América Latina.

A intenção é usar os biossimilares em lugar dos produtos biológicos de marca já existentes para tratamento de
'/>"/>

SOURCE Coherus BioSciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
2. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
3. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
4. Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference
5. Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)
6. L.S.E. (Barcelona) anuncia la primera financiación del antiplaquetario NmC por inversores españoles y suizos
7. RPS anuncia a Jonathan M. Fishbein, MD, como vicepresidente ejecutivo y jefe médico
8. RPS anuncia Jonathan M. Fishbein, MD como vice-presidente executivo e diretor médico
9. GenScript Anuncia Exposição Itinerante Junto com a Open Monoclonal Technology, Inc.
10. GenScript anuncia una muestra itinerante conjunta con Open Monoclonal Technology, Inc.
11. GenScript anuncia un programa conjunto con Open Monoclonal Technology, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014  Decision Resources Group finds that the market ... $7.7 billion by 2023 in the United States ... , Italy , Spain ... Japan . The biosimilar erosion of Roche/Genentech/Chugai,s ... out by the launch of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s ...
(Date:8/28/2014)... 28, 2014   Edison Nation Medical , ... worldwide search for product ideas to improve the ... ideas uncovered through the 6-month search ( www.EdisonNationMedical.com/Seniors ... manufacturers and healthcare retailers with whom Edison Nation ... individuals age 65 and older. The ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- Gateway Analytical announced today that they ... Annual Global Pharma Manufacturing Summit in ... The Global Pharma Manufacturing Summit offers a networking ... biologic pharmaceutical manufacturing. The conference is focused on ... such as the increasing pressure to grow and ...
Breaking Medicine Technology:The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3
... 14 Jane Staveley, a Principal Environmental Scientist for ... management services company, will moderate a distinguished panel of ... Concerns and Responses" during a briefing in the Rayburn ... be held from noon to 1:30 p.m. and is ...
... NEW YORK, Sept. 14 Reportlinker.com announces ... available in its catalogue: ... Assessment and Market Forecasts to 2016 ... Global Renal Dialysis Equipment Pipeline Analysis, ...
Cached Medicine Technology:ARCADIS' Jane Staveley to Moderate Congressional Briefing on Pharmaceuticals in Drinking Water 2Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 4Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 5Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 6Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 7Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 8Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 9Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 10Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 11Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 12
(Date:8/28/2014)... Lake Worth, FL (PRWEB) August 28, 2014 ... promote National Recovery Month throughout September. This month ... of addiction treatment and mental health services. Along ... Millennium Treatment Group is helping to spread the ... Month began in 1989, honoring the work of ...
(Date:8/28/2014)... American adults who are beginning to research ... now have a simpler way to connect with companies ... year, some of the best life insurance rates available ... The promoted plans that included price data revealed to ... policies. The term, guaranteed and modified plans that might ...
(Date:8/28/2014)... 2014 ABC television stars will join ... Show of Strength Telethon airing Sunday, Aug. 31, 9/8c ... raise funds and awareness to help save and improve ... disease. , Viewers tuning into the 2014 telethon to ... and introductions from some of the network’s leading stars, ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 ... announced today a regional partnership designed to advance ... planning for competitive young athletes, scholastic athletes and ... partnership’s Strong Body & Mind Initiative will offer ... both the physical and mental dynamics involved in ...
(Date:8/28/2014)... 28, 2014 Gurnick Academy of Medical ... program is re-accredited for the 5 years of the ... Technologists (ARMRIT). , “We are very proud to ... our program to make sure we provide the best ... interest in MRI field nowadays and I look forward ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2
... Medicine have just developed an advanced imaging technique to ... white blood cells. Microdomains are restricted areas on the ... molecules accumulate during cell activation. Using digital multi-channel videomicroscopy, ... and their forming microdomains in the vascular system in ...
... national guidelines recommend that, if managed, may have prevented ... in the issue of Neurology, the scientific journal of ... study of 1,040 people hospitalized for stroke or transient ... higher than recommended by national guidelines. TIA happens when ...
... But they are still just as sensitive as anyone else. Ignoring ... so//. ,Members of the "stronger sex" often expect a ... Many only consult a doctor when it's too late and could ... ,German men have a life expectancy of around 76 years, compared ...
... who smoke are increasingly at the risk of becoming ... turn into active TB disease//, according to an analysis ... Medicine. ,About one-third of the world’s population is ... the organism is usually rendered inactive by the immune ...
... molecular mechanisms behind most of the body’s sensing capabilities. Vision, ... pigment molecule that is extremely sensitive to light. It is ... decoded by the brain into visual information. But how the ... temperature has remained a mystery. ,“For a ...
... drug Vandetanib, marketed by London company AstraZeneca PLC// has begun. ... of lung cancer in whom the first-line treatment has failed. ... , The patients who have a recorded a case ... be given the once-daily drug Vandetanib in addition to pemetrexed, ...
Cached Medicine News:Health News:New Imaging Technique Tracks Traffic Patterns of White Blood Cells 2Health News:Cholesterol in Stroke Patients Exceeds National Guidelines 2Health News:Men Not as Tough as They Seem 2Health News:Susceptibility to TB is High Among the Smokers 2Health News:Researchers Discover Key to Body’s Ability to Detect Subtle Temperature Change 2Health News:Researchers Discover Key to Body’s Ability to Detect Subtle Temperature Change 3
This aron protects at 0.5 mm Pb equivalency and is 20% lighter than our Standard Back-Aid Apron - yet it contains no lead products that can be harmful to the environment!...
Protect your thyroid with a personal Thyroid Shield. While other shields have a rough, abrasive bias binding edging the neck, these have a softer, smoother turned seam that helps protect your neck fr...
Ties improve torso fit and transfer weight to waist and hips. Ties are 1"W cotton woven for flexibility and sewn at an angle across the full width of the two back sections for durability....
Use this workhorse apron where 360 of protection from direct and scatter radiation is required....
Medicine Products: